Evotec (ETR:EVT) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Evotec SE (ETR:EVT)’s stock price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of €4.28 and traded as low as €3.66. Evotec shares last traded at €3.85, with a volume of 709,422 shares changing hands.

Evotec Price Performance

The stock has a fifty day moving average of €4.28 and a 200-day moving average of €4.90. The firm has a market capitalization of $658.31 million, a P/E ratio of -3.84, a PEG ratio of 0.98 and a beta of 1.31. The company has a quick ratio of 2.97, a current ratio of 1.68 and a debt-to-equity ratio of 55.38.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.